1
|
Fine J, Allain L, Schlingemann J, Ponting DJ, Thomas R, Johnson GE. Nitrosamine acceptable intakes should consider variation in molecular weight: The implication of stoichiometric DNA damage. Regul Toxicol Pharmacol 2023; 145:105505. [PMID: 37805106 DOI: 10.1016/j.yrtph.2023.105505] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2023] [Revised: 09/15/2023] [Accepted: 10/02/2023] [Indexed: 10/09/2023]
Abstract
N-nitrosamines (NAs) are a class of compounds of which many, especially of the small dialkyl type, are indirect acting DNA alkylating mutagens. Their presence in pharmaceuticals is subject to very strict acceptable daily intake (AI) limits, which are traditionally expressed on a mass basis. Here we demonstrate that AIs that are not experimentally derived for a specific compound, but via statistical extrapolation or read across to a suitable analog, should be expressed on a molar scale or corrected for the target substance's molecular weight. This would account for the mechanistic aspect that each nitroso group can, at maximum, account for a single DNA mutation and the number of molecules per mass unit is proportional to the molecular weight (MW). In this regard we have re-calculated the EMA 18 ng/day regulatory default AI for unknown nitrosamines on a molar scale and propose a revised default AI of 163 pmol/day. In addition, we provide MW-corrected AIs for those nitrosamine drug substance related impurities (NDSRIs) for which EMA has pre-assigned AIs by read-across. Regulatory acceptance of this fundamental scientific tenet would allow one to derive nitrosamine limits for NDSRIs that both meet the health-protection goals and are technically feasible.
Collapse
Affiliation(s)
| | | | | | - David J Ponting
- Lhasa Limited, Granary Wharf House, 2 Canal Wharf, Leeds, UK
| | - Robert Thomas
- Lhasa Limited, Granary Wharf House, 2 Canal Wharf, Leeds, UK
| | - George E Johnson
- Institute of Life Science, Swansea University Medical School, Swansea, UK
| |
Collapse
|
2
|
Schlingemann J, Hickert S, Blom G, Kocks G, Allain L. Letter to the editor of Heliyon re: determination of dimethylamine and nitrite in pharmaceuticals by ion chromatography to assess the likelihood of nitrosamine formation Heliyon. 2021; 77: e06179. Heliyon 2022; 8:e09607. [PMID: 35734570 PMCID: PMC9207614 DOI: 10.1016/j.heliyon.2022.e09607] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2022] [Revised: 03/09/2022] [Accepted: 05/26/2022] [Indexed: 11/08/2022] Open
Abstract
Our letter to the editor of Heliyon outlines queries on the methodology and sample preparation used in article e06179, published in 2021. The nitrite measurements reported are higher than those observed in our experience. In the interest of reporting nitrite levels that are fully accurate, we would like to discuss the findings with the article authors.
Collapse
Affiliation(s)
| | | | - Giorgio Blom
- Chemical Development, Pharmaceutical Technology and Development, Operations, AstraZeneca, Macclesfield, UK
| | | | | |
Collapse
|
3
|
Boetzel R, Schlingemann J, Hickert S, Korn C, Kocks G, Luck B, Blom G, Harrison M, François M, Allain L, Wu Y, Bousraf Y. A Nitrite Excipient Database: A Useful Tool to Support N-Nitrosamine Risk Assessments for Drug Products. J Pharm Sci 2022; 112:1615-1624. [PMID: 35500671 DOI: 10.1016/j.xphs.2022.04.016] [Citation(s) in RCA: 22] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2022] [Revised: 04/25/2022] [Accepted: 04/25/2022] [Indexed: 10/18/2022]
Abstract
N-Nitrosamine risk assessment and control have become an integral part of pharmaceutical drug product development and quality evaluation. Initial reports of nitrosamine contamination were linked with the drug substance and its manufacturing process. Subsequently, the drug product and aspects of the formulation process have shown to be relevant. Regarding specific formulation contributions to nitrosamine content in a product, one risk lies in possible interactions between nitrosating agents, derived from nitrite in excipients, and vulnerable amines, either present as moieties of the active molecule or as impurities / degradants. However, the limited validated information on nitrite levels in excipients available until now, has been an obstacle for scientists to assess the risk of nitrosamine formation in pharmaceutical products. This has driven the creation of a database to store and share such validated information. The database, maintained by Lhasa Limited, constitutes a central platform to hold the data donated by the pharmaceutical company members on the nitrite concentrations in common excipients measured with validated analytical procedures. The goal of this data sharing initiative is to provide a common framework to contextualize and estimate the risk posed by presence of nitrites to contribute to the formation of nitrosamines in drug products. The major findings from the database analyses are: (1) average nitrite content and batch to batch variance differ among excipients, (2) for solid dosage forms, the nitrite contribution is dominated by the highest formula % excipients, e.g., the fillers (diluents), which are typically used in larger proportion, and are characterized by low nitrite levels and low variability, leading to an average value of 1 µg/g nitrite in a typical formulation, (3) substantial differences in average nitrite content in batches from different excipient vendors potentially reflecting differences in source materials or processing methods for excipient manufacturing. That final point suggests that future selection of raw materials or processing by excipient manufacturers may help reduce nitrite levels in finished drug product formulations, and thus the overall risk of nitrosamine formation in cases where the product contains vulnerable amines.
Collapse
|
4
|
Gaillard C, Allain L, Rouillon C, Desgue Y, Brucato S, Peyro-Saint-Paul L, Dompmartin A. No efficacy of biofield therapy in the treatment of warts of the hands and feet in adults: a randomized controlled trial. Clin Exp Dermatol 2021; 46:874-879. [PMID: 33639007 DOI: 10.1111/ced.14623] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2021] [Revised: 02/18/2021] [Accepted: 02/22/2021] [Indexed: 11/27/2022]
Abstract
Although biofield therapy is unexplained by scientific evidence, it has been practised for many years in numerous cultures for a variety of medical conditions. This study aimed to determine whether one session of biofield therapy with an experienced practitioner could treat warts on the hands and feet in adults. A single-blind, assessor-blind, placebo-controlled, randomized trial was performed between April 2016 and November 2018. The enrolled participants had at least one wart on the hand or foot that had been present for at least 90 days and they were not using any other therapy for the wart. The primary outcome of this trial was the disappearance of the original wart 3 weeks after session of proximal nontouch biofield therapy vs. a sham session. No original wart had disappeared 3 weeks after intervention (0/64), which made the study impossible to conclude on the primary objective. There were no significant differences between the two groups concerning wart disappearance 3 weeks (P = 0.49) or 6 weeks (P = 0.40) after the intervention. Reduction in wart size at Week 3 tended towards a better result for biofield therapy but this was not significant (P = 0.27). No related adverse effects were observed. The major limitation of this trial was the short follow-up time for measurement of clinical outcome, which did not allow verification of the hypothesis. However, this study shows that 3 weeks after a session of proximal nontouch biofield therapy is an insufficient length of time to assess biofield therapy in comparison with a sham session. Based on this study, biofield therapy cannot be recommended to treat warts within 3 weeks.
Collapse
Affiliation(s)
| | - L Allain
- Departments of, Clinical Research
| | | | - Y Desgue
- Biofield Therapy Center, 17 rue des ormes, F-50570, Marigny, France
| | | | | | - A Dompmartin
- Dermatology, Centre Hospitalier Universitaire de Caen, Caen, France
| |
Collapse
|
5
|
Allain L, Baertschi SW, Clapham D, Foti C, Lantaff WM, Reed RA, Templeton AC, Tønnesen HH. Implications of In-Use Photostability: Proposed Guidance for Photostability Testing and Labeling to Support the Administration of Photosensitive Pharmaceutical Products, Part 3. Oral Drug Products. J Pharm Sci 2016; 105:1586-1594. [PMID: 27056630 DOI: 10.1016/j.xphs.2016.02.035] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2016] [Revised: 02/19/2016] [Accepted: 02/24/2016] [Indexed: 10/22/2022]
Abstract
The ICH Q1B guidance and additional clarifying manuscripts provide the essential information needed to conduct photostability testing for pharmaceutical drug products in the context of manufacturing, packaging, and storage. As the previous 2 papers in this series highlight for drug products administered by injection (part 1) and drug products administered via topical application (part 2), there remains a paucity of guidance and methodological approaches to conducting photostability testing to ensure effective product administration. Part 3 in the series is presented here to provide a similar approach and commentary for photostability testing for oral drug products. The approach taken, as was done previously, is to examine "worst case" photoexposure scenarios in combination with ICH-defined light sources to derive a set of practical experimental approaches to support the safe and effective administration of photosensitive oral drug products.
Collapse
Affiliation(s)
- Leonardo Allain
- Merck Research Laboratories, Merck & Co., Inc., West Point, Pennsylvania 19486
| | | | | | - Chris Foti
- Gilead Sciences, Foster City, California 94404
| | - Wendy M Lantaff
- College of Pharmacy, Purdue University Indianapolis, Indiana 46202
| | | | - Allen C Templeton
- Merck Research Laboratories, Merck & Co., Inc., West Point, Pennsylvania 19486.
| | | |
Collapse
|
6
|
Fliszar KA, Walker D, Allain L. Profiling of metal ions leached from pharmaceutical packaging materials. PDA J Pharm Sci Technol 2006; 60:337-42. [PMID: 17260898] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/13/2023]
Abstract
Metal leachables from packaging components can affect the safety and efficacy of a pharmaceutical formulation. As liquid formulations continue to contain surfactants, salts, and chelating agents coupled with lower drug levels, the interaction between the formulation and the packaging material becomes more important. This study examines the interaction of commonly used packaging materials with extraction solvents representative of liquid formulations found in the pharmaceutical industry stressed under conditions encountered during accelerated stability studies.
Collapse
Affiliation(s)
- Kyle A Fliszar
- Merck Manufacturing Division, West Point, PA 19486, USA.
| | | | | |
Collapse
|
7
|
Garbi A, Allain L, Chorki F, Ourévitch M, Crousse B, Bonnet-Delpon D, Nakai T, Bégué JP. Novel [1,2]- and [2,3]-Wittig rearrangements of alpha-benzyloxy beta-CF(3)-beta-lactam enolates. Org Lett 2001; 3:2529-31. [PMID: 11483052 DOI: 10.1021/ol016198p] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
[reaction: see text] alpha-Benzyloxy alpha-CF(3)-beta-lactams are shown to offer the first examples of the enolate [1,2]- and enolate ortho-[2,3]-Wittig rearrangements which provide a unique entry to the alpha-benzyl-alpha-hydroxy lactams and the alpha-aryl-alpha-hydroxy lactams, respectively. Both products are potential precursors of new trifluoromethyl isoserines, and the latter is not accessible via the usual alkylation methodology.
Collapse
Affiliation(s)
- A Garbi
- BIOCIS, Centre d'Etudes Pharmaceutiques, rue J.B. Clément, Châtenay-Malabry F-92296 Cedex, France
| | | | | | | | | | | | | | | |
Collapse
|